文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

急诊就诊时无发热的脓毒症患者与抗生素治疗延迟相关

Afebrile status at the time of emergency department visit is associated with delayed antibiotic therapy in patients with sepsis (revised).
PubMed 文献 · Am J Emerg Med · 2024-07-02
一句话结论无发热脓毒症患者28天死亡风险更高(调整OR 1.76,95%CI 1.46-2.12),且接受抗生素更慢。

该回顾性多中心观察性研究纳入三家转诊医院共4293例脓毒症患者,按初始体温分为无发热组(<37.3 °C)和发热组(≥37.3 °C)。结果显示无发热组28天死亡的调整OR为1.76(95%CI 1.46-2.12),完成Hour-1集束化治疗记录亚组中调整OR为1.68(95%CI 1.34-2.11)。无发热组1小时内接受抗生素的比例为15.6%(323/2076),低于发热组的18.3%(395/2156)(p=0.02),且接受抗生素时间更长(209.3±277.9 vs 175.5±207.9,p<0.01)。作者认为需改进对无发热脓毒症患者的早期识别与治疗策略。

要点

  • 无发热脓毒症患者28天死亡调整OR为1.76(95%CI 1.46-2.12),高于发热患者。
  • 完成Hour-1集束化治疗记录的亚组中,无发热患者28天死亡调整OR为1.68(95%CI 1.34-2.11)。
  • 无发热组1小时内接受抗生素比例为15.6%(323/2076),低于发热组的18.3%(395/2156)(p=0.02)。
  • 无发热组接受抗生素时间较发热组长(209.3±277.9 vs 175.5±207.9,p<0.01)。
  • 28天存活者初始体温高于死亡者(37.5 °C±1.2 °C vs 37.1 °C±1.2 °C,p<0.01)。

适用人群与场景

  • 三家转诊医院的脓毒症患者,2014年5月至2016年2月按SEPSIS-2标准纳入,2016年3月至2020年4月按SEPSIS-3标准纳入。
  • 按初始体温分为无发热组(<37.3 °C)和发热组(≥37.3 °C)。

诊断标准与关键阈值

  • 体温分组阈值:无发热定义为<37.3 °C,发热定义为≥37.3 °C。
  • 脓毒症诊断标准:2014年5月至2016年2月采用SEPSIS-2标准,2016年3月至2020年4月采用SEPSIS-3标准。

研究设计与关键结果

  • 研究类型:回顾性多中心观察性研究,纳入三家转诊医院共4293例脓毒症患者。
  • 28天存活者初始体温显著高于28天死亡者(37.5 °C±1.2 °C vs 37.1 °C±1.2 °C,p<0.01)。
  • 多因素logistic回归显示无发热脓毒症患者28天死亡的调整OR为1.76(95%CI 1.46-2.12)。
  • 完成Hour-1集束化治疗记录的患者亚组中,无发热患者28天死亡调整OR为1.68(95%CI 1.34-2.11)。
  • 实施Hour-1集束化治疗后,无发热组1小时内接受抗生素比例为15.6%(323/2076),发热组为18.3%(395/2156)(p=0.02)。
  • 发热组接受抗生素速度快于无发热组(175.5±207.9 vs 209.3±277.9,p<0.01)。

证据类型、等级与局限

  • 证据类型:回顾性多中心观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,无发热脓毒症患者28天死亡风险更高且接受抗生素延迟,需改进对无发热脓毒症患者的早期识别与治疗策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether there is a difference in antibiotic administration time and prognosis in afebrile sepsis patients compared to febrile sepsis patients.

METHODS: This was retrospective multicenter observational study. Data collected from three referral hospitals. Data were collected from May 2014 through February 2016 under the SEPSIS-2 criteria and from March 2016 to April 2020 under the newly released SEPSIS-3 criteria. Patients were divided into two groups based on body temperature: afebrile (<37.3 °C) and febrile (≥37.3 °C). The relationship between initial body temperature and 28-day mortality were analyzed using multivariable logistic regression. The subgroup analysis was conducted on patients with complete Hour-1 bundle performance records.

RESULTS: We included 4293 patients in this study. Initial body temperatures in 28-day survivors were significantly higher than in 28-day non-survivors (37.5 °C ± 1.2 °C versus 37.1 °C ± 1.2 °C, p < 0.01). Multivariable logistic regression analysis was performed in afebrile and febrile sepsis patients. Adjusted odds ratio of afebrile sepsis patients for 28-day mortality was 1.76 (95% Confidence interval 1.46-2.12). As a result of performing the Hour-1 bundle, the number of patients who received antibiotics within 1 h was smaller in the afebrile sepsis patients (323/2076, 15.6%) than in the febrile sepsis patients (395/2156, 18.3%) (p = 0.02). In the subgroup analysis of patients with complete Hour-1 bundle performance records adjusted odds ratio of afebrile sepsis patients for 28-day mortality was 1.68 (95% Confidence interval 1.34-2.11). The febrile sepsis patients received antibiotics faster than the afebrile sepsis patients (175.5 ± 207.9 versus 209.3 ± 277.9, p < 0.01).

CONCLUSIONS: Afebrile sepsis patients were associated with higher 28-day mortality compared to their febrile counterparts and were delayed in receiving antibiotics. This underscores the need for improved early detection and treatment strategies for the afebrile sepsis patients.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kwak H, Kwon WY, Jo YH, et al. Afebrile status at the time of emergency department visit is associated with delayed antibiotic therapy in patients with sepsis (revised). Am J Emerg Med. 2024. PMID: 38976929. doi:10.1016/j.ajem.2024.06.031

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。